35 results about "Clostridium difficile infections" patented technology

The invention discloses a probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as a preparation method and application thereof, and belongs to the field of biological medicines. The FCPs and hyaluronic acid (HA) are combined through non-covalent interaction, so that the hydrogel has colon targeting property and mucosal adhesion at the same time, and delivery of probiotics is facilitated. The hydrogel (HF) based on polysaccharide has good biocompatibility, and can be used for effectively encapsulating the probiotics and the natural products. Then, the PDA-TH NPs and BA are incorporated into the polysaccharide chain network of HF, and finally the BA-HF-PDAT targeted co-delivery system is constructed. The BA (at) HF-PDAT targeted co-delivery system can protect BA from serious gastrointestinal stress, and is jointly assembled with PDT-TH NPs to realize dual slow release of thymol (Thy), so that the treatment effect of BA and Thy is improved, and the BA (at) HF-PDAT targeted co-delivery system contributes to treatment of clostridium difficile infection (CDI).

Disclosed herein are methods for administering a dose of a microbiota recovery therapy composition by colonoscopy. The methods disclosed herein are useful for the treatment of diseases and / or conditions of the digestive tract, such as Clostridium difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method can result in improved quality of life. These methods are capable of altering the gut microbiota composition and / or the gut metabolome composition. The microbiota recovery therapy composition comprises a fecal microbiota suspension comprising: a fecal microorganism derived from a human fecal sample, and a solution of polyethylene glycol and brine.

Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and / or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

The present application provides the use of a nanocomposite with a core-shell structure. Specifically, the present application provides the use of a nanocomposite with a core-shell structure in the preparation of a drug for preventing and / or treating Clostridium difficile infection and recurrent diseases caused thereby, wherein the nanocomposite comprises: ZnO nanoparticles as a core; mesoporous silica as a shell coated on the surface of the ZnO nanoparticles; an antibiotic loaded in the pore channel of the mesoporous silica; hyperbranched polylysine modified on the surface of the mesoporous silica; and a pH-responsive coating material as the outermost layer. The nanocomposite provided by the present application can achieve precise targeted release of the drug in the colon, and through the sequential and synergistic mechanism of "membrane breaking-sterilization-spore inhibition-repair", it can simultaneously solve multiple factors leading to CDI recurrence such as biofilm protection, spore storage, bacterial population destruction, mucosal damage, etc., and improve the treatment effect.

The invention relates to the field of bacteriostasis of clostridium difficile, in particular to bacillus coagulans, clostridium butyricum, a combination of the bacillus coagulans and the clostridium butyricum and application of the bacillus coagulans and the clostridium butyricum in relieving clostridium difficile infection. The bacillus coagulans is bacillus coagulans BC99 of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 21801, and the bacillus coagulans BC99 is a bacillus coagulans BC99 of which the preservation number is CGMCC NO. The clostridium butyricum is a clostridium butyricum CB39 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO. 33734, and the clostridium butyricum is a clostridium butyricum CB39 with the preservation number of CGMCC NO. The invention discloses inhibition effects of the bacillus coagulans, the clostridium butyricum and the combination thereof on clostridium difficile, and regulation and improvement of intestinal infection caused by the clostridium difficile.

The invention belongs to the technical field of chemical drugs, and particularly relates to application of a traditional Chinese medicine composition in preparation of drugs for treating recurrent clostridium difficile infection.The traditional Chinese medicine composition is prepared from 10-50 g of fresh ginger, 3-20 g of honey-fried licorice roots, 5-30 g of ginseng, 3-20 g of dried ginger, 3-30 g of scutellaria baicalensis, 3-30 g of pinellia ternate, 3-15 g of coptis chinensis and 10-30 g of Chinese dates. The traditional Chinese medicine composition is excellent in clinical effect, and in sample research on high-risk crowds such as old people and immunosuppression CDI relapse patients, the treatment scheme of the vancomycin combined with the ginger heart-fire purging decoction is remarkably superior to vancomycin single-drug treatment in the aspect of continuous clinical response rate at the main curative effect end point. This benefit is achieved mainly by reducing the recurrence rate of CDI by more than 60%. The combined scheme shows a robust curative effect in key subgroups such as the elderly and immunosuppressive subgroups, is good in safety, does not increase extra adverse event risks, and particularly does not observe renal function impairment.

A piezoelectric plate sensor comprising a piezoelectric layer; two electrodes; and an insulation layer. The insulation layer is produced by soaking the piezoelectric layer and two electrodes in a mercaptopropyltrimethoxysilane solution with an amount of water from 0.1 v / v. % to about 1 v / v % and at pH from about 8 to about 150 for a period from about 8 to about 15 hours, and the mercaptopropyltrimethoxysilane solution has a concentration of mercaptopropyltrimethoxysilane from about 0.01 v / v % to about 0.5 v / v %. A method of detecting a biomolecule in a sample using the piezoelectric plate sensor in particular, that of detecting a genetic marker with PCR sensitivity and specificity without the need of DNA isolation or amplification is also provided. The piezoelectric plate sensor may be used to diagnose various diseases including breast cancer, myocardial infarction, diarrhea, Clostridium difficile infection, and hepatitis B infection.

The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and / or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relates to methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two or three times.

The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

In an embodiment, the present disclosure pertains to a method of treating or preventing C. difficile infections. In some embodiments, the method includes administering an anti-toxin to a subject in need thereof. In some embodiments, the anti-toxin includes a designed ankyrin repeat protein (DARPin). In an additional embodiments, the present disclosure pertains to a composition including an anti-toxin for treating or preventing C. difficile infections. In some embodiments, the anti-toxin includes a DARPin. In some embodiments, the anti-toxin is a monomeric or dimeric DARPin for the neutralization of Clostridium difficile toxin B (TcdB).

To provide new and / or alternative therapeutic solutions which may alleviate the symptoms associated with Clostridium difficile infection, preferably intestinal infections, and / or cure the physiopathological conditions related to / associated therewith.SOLUTION: The present invention relates to the use of specific strains of Lactobacillus paracasei or of a composition comprising the strains for the prevention and / or treatment of a physiopathological condition related to / associated with Clostridium difficile infection, preferably intestinal infections, or so-called CD-associated disease (CDAD) or CD infection (CDI).SELECTED DRAWING: None

An insoluble cell fraction obtained from plant cells cultured in a suspension composed entirely of natural molecules for the treatment of primary and recurrent Clostridium difficile infections is provided. A process for the preparation of the insoluble cell fraction is also provided.

The present invention relates to a recombinant endolysin for controlling Clostridioides difficile infectious disease, and a use thereof, and, more specifically, to endolysin PHICD111_20024_EAD having excellent salt stability, and a use thereof. The endolysin PHICD111_20024_EAD, newly isolated in the present invention, exhibits specific activity against Clostridioides difficile, which is one of the causative bacteria of intestinal inflammation, and strains belonging to the genus Bacillus and Listeria monocytogenes, which are known as causative bacteria of food poisoning. The endolysin PHICD111_20024_EAD of the present invention does not affect humans and animals, and thus is safe and applicable to the pharmaceutical industry, food industry, biotechnology and the like, and also can effectively kill bacteria at a target site or target substance without problems related to antibacterial resistance.

Aspects herein concern cdtR mutations that can lead to reduced or absent virulence in C. difficile bacteria. Disclosed are compositions and methods using the cdtR mutants to treat or prevent C. difficile infections or diseases caused by C. difficile. Also disclosed are methods for detecting or determining C. difficile virulence based on mutation status of the cdtR gene in C. difficile.

The invention relates to the technical field of biosensing and medical instruments, in particular to an organic electrochemical transistor sensor and a preparation method and application thereof. According to the specific technical scheme, the surface of a grid electrode is sequentially modified with a mercaptoacetic acid self-assembly layer, an anti-clostridium difficile toxin B (TcdB) antibody (such as E3), ethanolamine and bovine serum albumin (BSA), and a biological function interface with high specific recognition and strong non-specific adsorption resistance is constructed. The preparation method is simple and stable. The obtained sensor has extremely high detection sensitivity (fg / mL level), good selectivity and a wide linear range on TcdB, can complete detection within a few minutes, is particularly suitable for rapid and accurate detection of TcdB in a complex biological sample, and has a wide application prospect in the field of bedside diagnosis of clostridium difficile infection.

The invention discloses an intestinal flora preparation based on polylactic acid microspheres and a preparation method of the intestinal flora preparation, and belongs to the technical field of biological medicines.The preparation comprises functional active flora and the polylactic acid microspheres loaded with the flora, the screened and extracted functional intestinal flora is combined with the biodegradable polylactic acid microspheres, and the functional active flora and the polylactic acid microspheres are combined to prepare the intestinal flora preparation based on the polylactic acid microspheres. The sustained release characteristic, adhesion and protection effect of the polylactic acid microspheres are utilized, the colonization rate, survival rate and durability of transplanted flora in the intestinal tract of a host are remarkably improved, and the preparation can be used for preparing drugs for treating related diseases caused by alteration of intestinal flora, such as clostridium difficile infection, inflammatory bowel disease, metabolic syndrome, autism and the like, and can be used for preparing medicines for treating related diseases caused by alteration of intestinal flora. The composition has the advantages of remarkable curative effect, good stability, convenience in use and the like.

The invention discloses an application of a phthalocyanine compound and a delivery system thereof in preparation of an anti-clostridium difficile toxin drug, and discovers that phthalocyanine can specifically target TFPI, CSPG4 and FZD1, 2, 7 receptor binding domains of clostridium difficile toxin B (TcdB), and effectively inhibits binding of toxin and host cells. In-vitro experiments prove that the phthalocyanine (Phthalocyanine, Pc) can be used for remarkably relieving the cytopathy induced by TcdB and has no cytotoxicity. In order to improve the curative effect, an extracellular vesicle (S-EV) from saccharomyces boulardii is creatively adopted to construct a drug loading system S-EV-Pc, and the pH responsive intestinal targeted delivery of the drug is realized. Animal experiments show that the preparation can significantly improve the survival rate of infected gerbil to 100%, significantly improve diarrhea symptoms, reduce intestinal TcdB load and relieve tissue pathological damage. The invention discloses the potential of phthalocyanine as a non-antibiotic small molecule drug in treatment of clostridium difficile infection (CDI) for the first time, and provides a brand new strategy and an experimental basis for developing a novel anti-CDI preparation.

The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C. difficile Toxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a C. difficile Toxin B. Also provided is the use of said antigens for the prevention / treatment / suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention / treatment / suppression of CDI.

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.

Compounds for use in the treatment of Clostridium difficile infection A compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use as medicament, wherein each

The invention relates to the technical field of molecular detection, in particular to a kit for rapidly detecting toxin-producing clostridium difficile and high-yield strains. The invention provides a multiple primer probe group aiming at tcdB, cdtA and tcdC delta 117 of clostridium difficile, and a kit for rapidly detecting toxin-producing genes of the clostridium difficile. The kit can be used for rapidly and accurately detecting toxin-producing genes of clostridium difficile clinically, continuously detects toxin-producing clostridium difficile, can also detect RT027 type high-yield strains, and has important significance for clinically and accurately diagnosing infection of clostridium difficile and investigating epidemiology.

The invention discloses application of beta-nicotinamide mononucleotide in preparation of a medicine for inhibiting clostridium difficile infection, and relates to the technical field of biomedicine. The invention discloses application of beta-nicotinamide mononucleotide in preparation of a medicine for inhibiting intestinal diseases caused by clostridium difficile infection. According to the invention, the beta-nicotinamide mononucleotide realizes systematic intervention on clostridium difficile infection through a dual core mechanism of down-regulating the expression of a proinflammatory factor and inhibiting a pyroptosis pathway mediated by metronidatin D; the anti-infection survival ability of a host can be remarkably enhanced, intestinal inflammation injury is relieved, the occurrence risk of complications such as pseudomembranous colitis is reduced, and the defect that dysbacteriosis is aggravated by traditional antibiotics is avoided; a brand new intervention strategy is provided for the public health emergency threat disease, namely, clostridium difficile infection, a foundation is laid for expanded application of beta-nicotinamide mononucleotide in the field of intestinal inflammatory diseases, and the beta-nicotinamide mononucleotide has prominent clinical transformation potential and academic research value.

The present invention relates to a bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573, and / or a culture supernatant thereof, for use in the treatment and / or prevention of a Clostridium difficile infection in an individual. The present invention also relates to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, and to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573.

The present invention relates to a bacterial strain of the species Faecalibacterium prausnitzii deposited at the CNCM under accession number CNCM I-4573 and / or its culture supernatant for use in the treatment and / or prevention of Clostridioides difficile infection in an individual.

Disclosed are vaccine compositions comprising polypeptides selected from Closlridioides difficile binary' toxin B, Closlridioides difficile binary toxin A, a High Molecular Weight portion of Closlridioides difficile Surface Layer Protein A, and a Low Molecular Weight portion of Closlridioides difficile Surface Layer Protein A. Methods of preparing the vaccine composition, methods of preventing or reducing attachment of C. difficile to an epithelial cell, and methods of preventing or treating a condition caused by infection of Closlridioides difficile are also provided.

The invention provides a prediction model construction system for occurrence and recurrence risks of clostridium difficile infection of inflammatory bowel diseases and a storage medium, and the system comprises a sampling module which is used for collecting excrement and age of sample people and antibacterial drug use condition information in a first preset time period; the data analysis module is used for obtaining a data set based on the excrement and the age of the sample crowd and the use condition information of the antibacterial agent in the first preset time period; the training module is used for respectively training a clostridium difficile infection occurrence risk prediction model and a clostridium difficile infection recurrence risk prediction model based on the data set; and the prediction module is used for inputting sampling data of a to-be-detected person into the trained clostridium difficile infection occurrence risk prediction model or clostridium difficile infection recurrence risk prediction model to obtain a prediction result. According to the method, prospective risk layering is realized through single-index biochemical quantification and a simple interpretable model.

The invention provides Escherichia coli YC49 and application of the Escherichia coli YC49 in inhibiting clostridium difficile in cooperation with bacteroides, and belongs to the technical field of microorganisms. The invention provides Escherichia coli YC49, and the preservation number of the Escherichia coli YC49 is CGMCC (China General Microbiological Culture Collection Center) No. 34488. The invention also provides an effect of the Escherichia coli YC49 and bacteroides on synergistically inhibiting clostridium difficile, and further provides a compound probiotic composition, an in-vitro antibacterial product and a coprophilous fungus transplantation product. The Escherichia coli YC49 can accelerate the whole process from growth to decline of clostridium difficile, and a culture solution obtained after the Escherichia coli YC49 is combined with common bacteroides or the Escherichia coli YC49 and the common bacteroides are co-cultured can remarkably inhibit growth of early-stage clostridium difficile, so that the Escherichia coli YC49 has application significance in treatment of clostridium difficile infection.

Single domain antibodies which bind to Clostridium difficile toxin B and their use in the treatment and prevention of Clostridium difficile infection. Nucleic acids and vectors encoding the single domain antibodies, host cells for expression of the single domain antibodies, methods of manufacture and compositions.

The present application relates to the technical field of medicine, specifically to a small molecule capable of inhibiting clostridium difficile infection, characterized by extracting alkaloids from white lotus seeds, wherein the alkaloids are lotus heart alkaloids. Experiments show that lotus heart alkaloids reduce the toxicity of TcdB by inhibiting the autophagy pathway and other effects, ultimately allowing actin to normally polymerize and depolymerize. In mechanism exploration, through cell surface binding experiments, it is found that the number of TcdB bound to cells is reduced in the presence of lotus heart alkaloids. These findings indicate that lotus heart alkaloids have an inhibitory effect on TcdB-induced cytotoxicity. Compared with metronidazole and vancomycin, which are traditionally used to inhibit clostridium difficile infection, lotus heart alkaloids have less frequent drug resistance and less negative impact on intestinal flora, ensuring the therapeutic efficacy.